EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Mira Pharmaceuticals's enterprise value is $6.15 Mil.
Mira Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Mira Pharmaceuticals's EV-to-Revenue for today is .
The historical rank and industry rank for Mira Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
MIRA's EV-to-Revenue is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.41 * Ranked among companies with meaningful EV-to-Revenue only.
Mira Pharmaceuticals EV-to-Revenue Historical Data
The historical data trend for Mira Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mira Pharmaceuticals's EV-to-Revenue
For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mira Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Mira Pharmaceuticals's EV-to-Revenue falls into.
Mira Pharmaceuticals's current Enterprise Value is $6.15 Mil.
Mira Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mira Pharmaceuticals (NAS:MIRA) EV-to-Revenue Explanation
Mira Pharmaceuticals's share price for today is $0.655.
Mira Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mira Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Mira Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Mira Pharmaceuticals (Mira Pharmaceuticals) Business Description
Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Its target patient population is also typically presenting with chronic pain. its drug candidate, MIRA1a, if approved by the FDA, maybe a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by the company, it believes that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MIRA has been successfully added to your 